Education
About Us
Working with TipRanks
Follow Us
Merck & Company (MRK)
NYSE:MRK
MRK Stock Chart & Stats
Day’s Range― - ―
52-Week Range$73.31 - $120.30
Previous CloseN/A
Volume3.30M
Average Volume (3M)11.59M
Market Cap
$215.01B
Enterprise Value$225.73B
Total Cash (Recent Filing)$9.23B
Total Debt (Recent Filing)$34.84B
Price to Earnings (P/E)13.3
Beta0.45
Next Earnings
Oct 30, 2025EPS Estimate
2.37Next Dividend Ex-Date
Sep 15, 2025Dividend Yield3.66%
Share Statistics
EPS (TTM)2.13
Shares Outstanding2,497,783,200
10 Day Avg. Volume10,006,851
30 Day Avg. Volume11,593,947
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)0.00
Price to Sales (P/S)0.00
P/FCF Ratio0.00
Enterprise Value/Market Cap1.05
Enterprise Value/Revenue3.53
Enterprise Value/Gross Profit4.62
Enterprise Value/Ebitda8.66
Forecast
1Y Price Target
$101.93Price Target Upside16.66% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering16
Bulls Say, Bears Say
Bulls Say
Product DevelopmentPerformance from the company’s key new product cycle, Winrevair, remains intact with optimism on potential label expansion and data from the HYPERION trial.
Revenue GrowthGrowth in the pneumococcal vaccine franchise is encouraging, with Vaxneuvance exceeding expectations and Capvaxive gaining market share.
Strategic InitiativesThe newly announced $3bn optimization initiative is viewed as a sensible re-allocation of capital to fund new launches and R&D.
Bears Say
Inventory ManagementMRK has no shipments planned for Gardasil in China at least through the end of this year due to elevated inventories and soft demand.
Market UncertaintyUncertainty around Merck's Gardasil franchise and lack of clarity around growth beyond the Keytruda LOE will continue to pressure shares.
Vaccine DemandZhifei, MRK’s local China distribution partner for the company’s HPV vaccine Gardasil, missed results, noting consumer demand for HPV vaccines in China has not yet recovered.
Merck & Company News
MRK FAQ
What was Merck & Company’s price range in the past 12 months?
Merck & Company lowest stock price was $73.31 and its highest was $120.30 in the past 12 months.
What is Merck & Company’s market cap?
Merck & Company’s market cap is $215.01B.
When is Merck & Company’s upcoming earnings report date?
Merck & Company’s upcoming earnings report date is Oct 30, 2025 which is in 67 days.
How were Merck & Company’s earnings last quarter?
Merck & Company released its earnings results on Jul 30, 2025. The company reported $2.13 earnings per share for the quarter, beating the consensus estimate of $2.033 by $0.097.
Is Merck & Company overvalued?
According to Wall Street analysts Merck & Company’s price is currently Undervalued.
Does Merck & Company pay dividends?
Merck & Company pays a Quarterly dividend of $0.81 which represents an annual dividend yield of 3.66%. See more information on Merck & Company dividends here
What is Merck & Company’s EPS estimate?
Merck & Company’s EPS estimate is 2.37.
How many shares outstanding does Merck & Company have?
Merck & Company has 2,497,783,200 shares outstanding.
What happened to Merck & Company’s price movement after its last earnings report?
Merck & Company reported an EPS of $2.13 in its last earnings report, beating expectations of $2.033. Following the earnings report the stock price went down -1.065%.
Which hedge fund is a major shareholder of Merck & Company?
Currently, no hedge funds are holding shares in MRK
Merck & Company Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$101.93 (16.66% Upside)
$101.93 (16.66% Upside)
Blogger Sentiment
Bullish
MRK Sentiment 90%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Increased
By 1.7M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Positive
Last 7 Days ▲ 0.6%
Last 30 Days ▲ 1.4%
Last 30 Days ▲ 1.4%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-22.50%
12-Months-Change
Fundamentals
Return on Equity
35.44%
Trailing 12-Months
Asset Growth
4.34%
Trailing 12-Months
Company Description
Merck & Company
Merck & Company, known as Merck Sharp & Dohme (MSD) outside the United States and Canada, is a leading global healthcare company dedicated to discovering, developing, and providing innovative medicines, vaccines, and animal health products. Founded in 1891, Merck operates in two primary sectors: Human Health, which includes prescription medicines, vaccines, biologics, and over-the-counter products, and Animal Health, which offers a range of products for livestock and companion animals. The company is renowned for its contributions to medical science, including advancements in oncology, infectious diseases, and vaccines.
MRK Company Deck
MRK Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call highlighted Merck's strong performance with new product launches and a robust pipeline, particularly in oncology and cardiopulmonary. However, challenges in China with GARDASIL and competitive pressures from biosimilars were notable lowlights.View all MRK earnings summariesMRK Sales Breakdown
89.45% Pharmaceutical
9.16% Animal Health
1.39% Other
MRK Stock 12 Month Forecast
Average Price Target
$101.93
▲(16.66% Upside)
Technical Analysis
Ownership Overview
0.05% Insiders
20.69% Mutual Funds
13.15% Other Institutional Investors
40.79% Public Companies and Individual Investors